Key Points
Eli Lilly and Novo Nordisk are leading the GLP-1 drug market with their injectables, Zebound and Wegovy, and have recently launched oral versions, Foundayo and oral Wegovy, respectively. The GLP-1 market is projected to approach $100 billion by the end of the decade.
In a strategic move, Amazon has announced a weight management program through Amazon One Medical, integrating GLP-1 treatments into a comprehensive healthcare approach. This program will utilize Amazon’s established network to provide virtual and in-person consultations, prescription renewals, and swift delivery of medications like Foundayo and oral Wegovy. Amazon aims to capitalize on the growing demand for these treatments, with same-day delivery available in nearly 3,000 cities across the U.S.
As Amazon seeks to enhance its healthcare offerings, the success of this weight management program could significantly boost its Amazon One Medical sector amid rising patient interest in GLP-1 drugs.
